Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00428545 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab and Bortezomib in Patients With Advanced Malignancy
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
NCT00428545: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00428545 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 104 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00428545, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of Avastin™ (bevacizumab) and Velcade™ (bortezomib) that can be given in combination to patients with a metastatic or unresectable advanced malignancy. The safety and effectiveness of this drug combination will also be studied.
Primary Outcome
The MTD is defined as the highest dose studied in which the incidence of DLT was less than 33%.
Interventions
- DRUG Bevacizumab
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2007-01 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
What the finished NCT00428545 record still lists
NCT00428545 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% higher).
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00428545 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00428545 about?
NCT00428545 is a clinical study titled "Bevacizumab and Bortezomib in Patients With Advanced Malignancy". The goal of this clinical research study is to find the highest tolerable dose of Avastin™ (bevacizumab) and Velcade™ (bortezomib) that can be given in combination to patients with a metastatic or unresectable advanced malignancy. The safety and effectiveness of this drug combination will also be st...
What is the current status of trial NCT00428545?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2007-01. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00428545?
The interventions under investigation include: Bevacizumab (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00428545?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00428545's enrollment target sits among peer trials
104 536th of 2000 higher than 1,460 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia